providing wide range of innovative and cost-effective preclinical pharmacology R&D services focusing on cardiovascular (infarction, heart failure, stroke, sepsis, arrhythmias, etc) and metabolic diseases (diabetes, dyslipidemia, atherosclerosis, obesity, uremia, etc) with strong scientific support
clinical R&D services focusing on unique clinical studies including medical devices that need sensitive patient population and thereby strong regulatory & scientific support
to manage internal R&D projects to develop new technologies for out-licensing in the fields of diagnosis and therapy of cardiovascular and metabolic disease
Full service: creative, cost-effective, flexible, high quality 20-year experience in drug-development with many sucess stories.
Scientific support based on international scientific excellence (publications over 200, impact factors over 700, citations over 10.000).
Internationally trained management & staff (MDs, PhDs, clinical pharmacologists, PharmDs, chemists, biologists, medical engineers, MBA quality managers).
Complex platforms of cardiovascular and metabolic disease models.
Custom design models with co-morbidities, including large animals.
Strong biochemical and molecular biological background for complex proof-of-concept studies.
Strict confidentiality, IP law of the European Union.
Péter Ferdinandy, MD, PhD, MBA clinical pharmacologist
Peter Ferdinandy received an MD diploma in 1991 and a PhD degree in 1995 from the University of Szeged. He became a registered clinical pharmacologist in 1999, and obtained his DSc degree of the Hungarian Academy of Sciences in 2004. He completed MBA studies in Finance and Quality Management in 2004 at the Budapest University of Technology and Economics. He worked for 2 years at the Department of Pharmacology, University of Alberta, Edmonton, Canada, as a postdoctoral fellow of MRC Canada. He was the head of the Cardiovascular Projects at Biorex Co (a partner of Abbott), a US-Hungarian biotech company, and consulted preclinical and clinical pharmacological projects for several pharmaceutical companies all over the world in the last 20 years. He was the founder of the Cardiovascular Research Group at the University of Szeged, see www.cardiovasc.com. He is a professor of pharmacology and clinical pharmacology, head of the Department of Pharmacology and Pharmacotherapy, Semmelweis University. He published over 200 papers in international peer-reviewed journals with an impact factor over 800 and over 10.000 citations. He is member of the editorial boards of Br J Pharmacol, Basic Res Cardiol, J Mol Cell Cardiol, and J Pharmacol Toxicol Methods. He is the past president of the International Society for Heart Research, European Section, chair of the Working Group of Cellular Biology of the Heart, European Society of Cardiology.
Anikó Görbe, MD, PhD Clinical Chemist, Psychotherapist
Anikó Görbe received an MD diploma in 1997 and a PhD degree in 2007 from the University of Szeged, Hungary. She became a registered Clinical Chemist in 2002, and a Psychotherapist in 2011. She worked for 1 year at the Department of Anatomy and Developmental Biology, University of London, London, UK, as a research fellow of the Wellcome Trust Foundation. Currently she is an associate professor at the Department of Pharmacology and Pharmacotherapy, Semmelweis University Budapest, Hungary. She performed her habilitation in 2015 in theoretical medical sciences at University of Szeged. She published over 35 papers in international peer-reviewed journals with a cumulative impact factor over 140 and citations close to 800.
Eszter Fodor, MD, clinical pharmacologist, pediatrician
Eszter Fodor is a registered Pediatrician and Clinical Pharmacologist as well as Certified Physician of Health Economy and Health Management.
She has worked as a pediatrician and as a sports medicine physician, and then joined large pharmaceutical companies Gedeon Richter Pharmaceuticals and Sanofi-Aventis, as a medical representative, project leader, and then world-wide CROs such as Quintiles and INC research, as a clinical operation manager. In 2009, she became the clinical director of Pharmahungary.
She has more than 15 years of experience in managing clinical studies with drug, medical device and combination products from start-up to closure, in a wide range of therapeutic indications.
Péter Bencsik, MD, PhD
Péter Bencsik received an MD diploma in 2003 and a PhD degree in 2008 from the University of Szeged, Hungary. He joined Pharmahungary in 2007. He gained research experience at the Institut für Pathophysiologie, Universitätsklinikum Essen, Univerity of Essen, Germany in 2005 and at Inserm U886, Université Claude Bernard Lyon I, Lyon, France in 2010. He published over 30 papers in international peer-reviewed journals with a cumulative impact factor over 120 and citations over 800.
Zoltán Giricz, PharmD, PhD
Zoltán Giricz received an PharmD diploma in 2001 and a PhD degree in 2006 from the University of Szeged, Hungary. He joined Pharmahungary in 2012. He gained research experience at National University of Ireland, Galway in 2007-2009 and at the San Diego State University, San Diego, California in 2009-2011. He published 35 papers in international peer-reviewed journals with a cumulative impact factor over 110 and citations close to 1500.
Lilla Wenszky, MSc
Lilla Wenszky received a BSc diploma in economics and economy teacher in 2005 from the Budapest Business School, Hungary and a MSc diploma in economics in 2008 from the Budapest University of Technology and Economics. She joined Pharmahungary Group in 2010. She gained work experience at a large international corporation from 2006 to 2009 as an accountant and later as a general ledger team leader.
András Nógrádi, MSc
András Nógrádi received his MSc diploma in 2011 from Eötvös Loránd University, Faculty of Law as a political scientist. He has joined Pharmahungary Group in 2011 as Business Development Assistant and acts as Business Development Manager and R&D Coordinator since 2013.
As a Business Development Manager he is responsible for all business development and commercialization processes of Pharmahungary Group, including B2B meetings on international partnering conferences. As an R&D Coordinator his task is to assist in Competent Authority, Central Ethics Committee submissions, coordinating clinical trials, and preclinical R&D projects including large animal studies.
Justus-Liebig University, Giessen, Germany
Rainer Schulz had established and led an independent research group within the Department of Pathophysiology, University of Essen, Medical School, and has (since January 2011) been appointed as Chairman of Physiology at the Justus-Liebig University Giessen. His research group uses a translational approach from subcellular particles towards large animal model to define new targets involved in ischemia/reperfusion injury and investigate novel treatment strategies for protecting the heart. Professor Schulz received the Young Investigator Award from the European Society of Cardiology (ESC), the Fraenkel and Franz-Groedel Award as well as the Basic Science Lecture Award of the German Cardiac Society. Dr. Schulz served as Chairman of the Working Group on Cellular Biology of the Heart of the ESC and he is currently member of the International Council of the Society of Heart Research (ISHR) and the program committee of the German Cardiac Society. Since 2001 he has published more than 160 peer-reviewed articles and wrote 5 book chapters. His H-index is 70 with a total number of citations over 16,400. Prof. Schulz is the Associate Editor of Cardiovascular Research (from February 2011) and the British Journal of Pharmacology (since 2008) and he serves on the Editorial Board of several cardiovascular journals. He has successfully collaborated with other research teams nationally and internationally including Pharmahungary’s CEO, Prof. Peter Ferdinandy, as indicated by numerous co-authored publications.
Vice-President, Binutra Inc., Cape Town, South Africa
Jacques van Rooyen graduated from Stellenbosch University with a PhD (Physiology) in 1994. He worked in the Heart Research Unit of Prof Lionel Opie at the University of Cape Town and took up an academic position as senior lecturer at the Stellenbosch University in 1994. His research focused on the effect of dietary oil intervention in cardiac health. He became a leading researcher on the effect of red palm oil in cardiac health and protection and his team published more than 20 papers on red palm oil supplementation and heart protection. His total scientific contribution include more than 30 peer reviewed papers, 12 MSc and PhD students. In 2006 he also pursued an industry approach and encapsulated red palm in a hard gelatin capsule. In 2011 his South African company, Bio-Cap Technologies, filed 3 patents on a specific delivery mechanisms and also designed proprietary formulations with red palm oil. From 2007-2013 he was Honorary Professor and Adjunct Professor at the Cape Peninsula University of Technology in South Africa. Currently he is the Vice-President of the USA based Binutra Inc and Executive Director of Bio-Cap Technologies in South Africa, two companies that are involved in novel delivery systems, equipment development and proprietary formulations.
Managing Director and Chief Executive Officer, Cellmid, Sydney, Australia
Maria Halasz has been involved with biotechnology companies for over 22 years; initially working in executive positions in biotechnology firms, then managing investment funds and later holding senior positions in corporate finance specialising in life sciences.
Since taking over as Chief Executive and Managing Director of Cellmid, Maria has led the restructuring of the business, the acquisition of the midkine and Advangen intellectual property portfolios and the recapitalisation of the company. An accomplished public company CEO with international experience, Maria has executed transactions in the US, China, Europe, Japan and the UK.
Maria is a graduate of the University of Western Australia (B.Sc., MBA) and the Australian Institute of Company Directors. She has board experience in public and private companies, and has acted on advisory boards of non-profit organisations.